Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Ollie Hinkle Heart Foundation reposted!recent partners VPT
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(91)
•••
Comment by jopatcloon Mar 22, 2024 9:23am
55 Views
Post# 35946776

RE:Ollie Hinkle Heart Foundation reposted!recent partners VPT

RE:Ollie Hinkle Heart Foundation reposted!recent partners VPTgood comment 
@cardinal next week should be our week #next week
@Anima good to see ollie is still thinking about VPT
 
2
@Synergy If good news drops now there is not much on the Ask to slow down a run imo. Low volume is good, it means no one is selling and the short pool dried up.
 
3
jopatclo wrote:  Interesting repost of Ollie Hinkle Heart Foundation
View Ollie Hinkle Heart Foundation
Ollie Hinkle Heart Foundation reposted this
Richard Simpson
Excellent quotes from recent Ventripoint Diagnostics Ltd. partners:

Prof. Felix Berger, Director of the Clinic for Congenital Heart Disease – Pediatric Cardiology at DHZC stated, "VMS+ not only gives us a very precise spatial view of complex congenital malformations at any time, but it also provides us with important data on the function of the heart muscle. This allows us to plan therapy even more precisely, check it at any time and adjust it if necessary.”

Dr. Saleha Kabir, Lead Physiologist in Paediatrics and Advanced Echocardiography stated (Evelina Hospital): "...The new VMS + system with its increased functionality is a great addition to our echo lab. The more compact console increases accessibility and mobility which allows us to use it in a variety of settings and the simplified workflow makes image acquisition faster, which is fantastic for our small and easily distracted paediatric patients!"

“We think Ventripoint is a game-changer for children with heart disease,” said Beth Rumack, the Chief Operating Officer of the OHHF. “You no longer need to take a child down to an MRI suite, which entails a whole team of technicians and often means having to put the child under anesthesia, so they don’t move during the MRI scan.

#echofirst #medtech #cardiology #pediatrics Ollie Hinkle Heart Foundation



@Synergy If good news drops now there is not much on the Ask to slow down a run imo. Low volume is good, it means no one is selling and the short pool dried up.
 
3
 
@Synergy I was looking at my own banks Venture lvl 2 live when I made those comments. :)

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities